144 -10 (60) 2023 — Zhabborova D.H., Yuldasheva G.R. — ASSESSMENT OF THE EFFECTIVENESS OF USE OF ENZYME REPLACEMENT THERAPY IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE AND PANCREATIC STEATOSIS

ASSESSMENT OF THE EFFECTIVENESS OF USE OF ENZYME REPLACEMENT THERAPY IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE AND PANCREATIC STEATOSIS

Zhabborova D.H., Tashkent State Dental Institute Uzbekistan

Yuldasheva G.R. Center for the Development of Professional Qualifications of Medical Workers under the Ministry of Health of the Republic of Uzbekistan

Resume

A study of 60 patients with non-alcoholic fatty liver disease and pancreatic steatosis in combination with exocrine pancreatic insufficiency showed that the use of enzyme replacement therapy with the drug Creon 25 U stopped the pain syndrome, and the content of neutral fat and fatty acids in the feces decreased. With enzyme replacement therapy, patients subjectively began to feel better, complaints of flatulence decreased, and stool returned to normal. As a result, of the clinical study, patients and specialists concluded that the use of Creon 25 U is an effective method in the treatment of not only exocrine pancreatic insufficiency, but also other pathological conditions that are accompanied by digestive disorders, especially when there was severe pain.

Keywords: non-alcoholic fatty liver disease, pancreatic steatosis, exocrine pancreatic insufficiency, abdominal syndrome

First page

830

Last page

833

For citation: Zhabborova D.H., Yuldasheva G.R. – ASSESSMENT OF THE EFFECTIVENESS OF USE OF ENZYME REPLACEMENT THERAPY IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE AND PANCREATIC STEATOSIS //New Day in Medicine 2023 10(60): 830-833 https://newdaymedicine.com/index.php/2023/12/27/l-703/

LIST OF REFERENCES:

1. Белоусова Е.А., Никитина Н.В., Мишуровская Т.С., Цодиков Г.В. Синдром абдоминальной боли при хроническом панкреатите // Фарматека. 2007;29-34.
2. Клинические рекомендации Научного общества гастроэнтерологов России – Rotonya M. Carr, MD, Amanke Oranu, MD, and Vandana Khungar, MD Non- alcoholic fatty liver disease: Pathophysiology and management, MScGastroenterol Clin North Am. 2016 Dec; 45(4):639-652.
3. Fang Y.L., Chen H., Wang C.L., Liang L. Pathogenesis of non-alcoholic fatty liver disease in children and adolescence: from “two hit theory” to “multiple hit model”. // World J Gastroenterol. 2018;24:2974-83. DOI: 10.3748/wjg.v24.i27.2974
4. Nair R.J., Lawler L., Miller M.R. Chronic Pancreatitis // Am Fam Physician. 2007;76(11):1679-1688.
5. Xian Y.X., Weng J.P., Xu F. MAFLD vs. NAFLD: shared features and potential changes in epidemiology, pathophysiology, diagnosis, and pharmacotherapy. // Chin Med J. 2020;134:8-19.
6. Parthasarathy G., Revelo X., Malhi H. Pathogenesis of Nonalcoholic Steatohepatitis: An Overview. // Hepatology Communications. 2020;4(4):478-92. DOI: 10.1002/hep4.1479